CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Cetrotide acetatedrug
Likely dose
Cetrotide acetate 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00867659
NCT00867659N/ACompleted
CompareCT.gov

The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome in Oocyte Donors

Virginia Center for Reproductive Medicine·interventional·Posted Mar 24, 2009·Updated Mar 27, 2013

In Brief

A clinical study evaluating Cetrotide acetate for Ovarian Hyperstimulation Syndrome. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This pilot study aims to address whether the prophylactic use of Cetrorelix Acetate after a long gonadotropin-releasing hormone (GnRH) agonist protocol post-hCG (human chorionic gonadotropin) administration can significantly reduce the incidence of OHSS in oocyte donors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Hyperstimulation Syndrome
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 24, 2009
Enrollment StartMar 1, 2009
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 17.3 years ago

Interventions

Cetrotide acetatedrug

cetrotide acetate is a GnRH antagonist. The dose is 3 mg once on the day of oocyte retrieval.